MA55017A - Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiés - Google Patents
Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiésInfo
- Publication number
- MA55017A MA55017A MA055017A MA55017A MA55017A MA 55017 A MA55017 A MA 55017A MA 055017 A MA055017 A MA 055017A MA 55017 A MA55017 A MA 55017A MA 55017 A MA55017 A MA 55017A
- Authority
- MA
- Morocco
- Prior art keywords
- monosaccharidic
- eukaryot
- labeling
- diagnosis
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/02—Monosaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305202 | 2019-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55017A true MA55017A (fr) | 2021-12-29 |
Family
ID=65766918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055017A MA55017A (fr) | 2019-02-20 | 2020-02-20 | Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiés |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220146516A1 (fr) |
| EP (1) | EP3928097A1 (fr) |
| JP (1) | JP2022521528A (fr) |
| KR (1) | KR20210132097A (fr) |
| CN (1) | CN113677997A (fr) |
| AU (1) | AU2020225034A1 (fr) |
| BR (1) | BR112021016399A2 (fr) |
| CA (1) | CA3129125A1 (fr) |
| EA (1) | EA202192289A1 (fr) |
| IL (1) | IL284854A (fr) |
| MA (1) | MA55017A (fr) |
| MX (1) | MX2021009987A (fr) |
| SG (1) | SG11202108422XA (fr) |
| WO (1) | WO2020169782A1 (fr) |
| ZA (1) | ZA202106893B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3188425A1 (fr) * | 2020-08-19 | 2022-02-24 | Sam Dukan | Procedes et kit de marquage de cellules eucaryotes a partir d'un organisme multicellulaire a l'aide de composes monosaccharidiques modifies et composition pharmaceutique comprenant ces cellule |
| WO2022038198A1 (fr) * | 2020-08-19 | 2022-02-24 | Diamidex | Composé monosaccharidique pour le marquage de la sécrétion cellulaire |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050004044A1 (en) * | 2003-04-07 | 2005-01-06 | Board Of Regents | Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics |
| EP1987068B1 (fr) * | 2006-02-10 | 2018-08-08 | Life Technologies Corporation | Modification des oligosaccharides et marquage des protéines |
| US10191060B2 (en) * | 2009-11-09 | 2019-01-29 | University Of Washington | Functionalized chromophoric polymer dots and bioconjugates thereof |
| US9809560B2 (en) * | 2010-08-09 | 2017-11-07 | Albert Einstein College Of Medicine, Inc. | Ligands and methods for labeling biomolecules in vivo |
| KR101159172B1 (ko) | 2011-11-24 | 2012-08-07 | 학 성 김 | Id카드이용 선후불겸용결제 방법 및 시스템 |
| EP2617833A1 (fr) | 2012-01-18 | 2013-07-24 | Centre National de la Recherche Scientifique (CNRS) | Procédé de détection spécifique de bactéries vivantes |
| EP3091081A1 (fr) | 2015-05-04 | 2016-11-09 | Centre National de la Recherche Scientifique (CNRS) | Procédé pour marquer spécifiquement des bactéries vivantes comprenant l'utilisation de composés de monosaccharide modifiés |
| EP3371200A4 (fr) * | 2015-10-07 | 2020-04-29 | The Board of Trustees of the University of Illinois | Précurseurs métaboliques de sucre, activables par un déclencheur pour le marquage et le ciblage sélectif d'un cancer |
| EP3170830A1 (fr) * | 2015-11-17 | 2017-05-24 | Centre National De La Recherche Scientifique | Nouveaux composés de 5-azido-5-deoxy-2 : 3-isopropylidene-d-arabinose ; leur procédé de fabrication et leur utilisation pour la synthèse de ara-n3, kdo-n3 et 4ekdo-n3 |
-
2020
- 2020-02-20 CN CN202080015413.0A patent/CN113677997A/zh active Pending
- 2020-02-20 KR KR1020217029710A patent/KR20210132097A/ko unknown
- 2020-02-20 MA MA055017A patent/MA55017A/fr unknown
- 2020-02-20 US US17/432,331 patent/US20220146516A1/en active Pending
- 2020-02-20 AU AU2020225034A patent/AU2020225034A1/en not_active Abandoned
- 2020-02-20 EA EA202192289A patent/EA202192289A1/ru unknown
- 2020-02-20 CA CA3129125A patent/CA3129125A1/fr active Pending
- 2020-02-20 WO PCT/EP2020/054567 patent/WO2020169782A1/fr unknown
- 2020-02-20 EP EP20707049.1A patent/EP3928097A1/fr active Pending
- 2020-02-20 BR BR112021016399-9A patent/BR112021016399A2/pt unknown
- 2020-02-20 SG SG11202108422XA patent/SG11202108422XA/en unknown
- 2020-02-20 JP JP2021549192A patent/JP2022521528A/ja active Pending
- 2020-02-20 MX MX2021009987A patent/MX2021009987A/es unknown
-
2021
- 2021-07-14 IL IL284854A patent/IL284854A/en unknown
- 2021-09-17 ZA ZA2021/06893A patent/ZA202106893B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3129125A1 (fr) | 2020-08-27 |
| SG11202108422XA (en) | 2021-09-29 |
| BR112021016399A2 (pt) | 2021-10-19 |
| WO2020169782A1 (fr) | 2020-08-27 |
| IL284854A (en) | 2021-08-31 |
| AU2020225034A1 (en) | 2021-08-19 |
| KR20210132097A (ko) | 2021-11-03 |
| JP2022521528A (ja) | 2022-04-08 |
| MX2021009987A (es) | 2021-11-04 |
| EP3928097A1 (fr) | 2021-12-29 |
| US20220146516A1 (en) | 2022-05-12 |
| EA202192289A1 (ru) | 2021-11-17 |
| ZA202106893B (en) | 2023-06-28 |
| CN113677997A (zh) | 2021-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55017A (fr) | Procédés de marquage de cellules eucaryotes à partir d'un organisme multicellulaire ainsi que pour le traitement et/ou le diagnostic d'un cancer à l'aide de composés monosaccharidiques modifiés | |
| MA52494A (fr) | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation | |
| MA53096A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting | |
| MA50417A (fr) | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang | |
| MA43404A (fr) | Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques | |
| EP3555629A4 (fr) | Utilisation de gènes à médiation par motif apoe4 pour le diagnostic et le traitement de la maladie d'alzheimer | |
| MA47079B1 (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
| MA33662B1 (fr) | Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète | |
| MA55974A (fr) | Composés triaryles pour le traitement de maladies pd-l1 | |
| MA34234B1 (fr) | Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation | |
| MA47469A (fr) | Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer | |
| BR112014031414A2 (pt) | métodos de detectar doenças ou condições utilizando células doentes circulantes | |
| MA51422A (fr) | Inoculant de fonte et procédé de production d'inoculant de fonte | |
| MA46459B1 (fr) | Méthode de traitement de lésions rénales aiguës | |
| TN2020000072A1 (en) | Psma ligands for imaging and endoradiotherapy | |
| MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| MA47215A (fr) | Procédés prédictifs et diagnostiques pour le cancer de la prostate | |
| MA55532A (fr) | Composés de neuréguline-4 et procédés d'utilisation | |
| MA38307A1 (fr) | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale | |
| Spindler | The basal Sphenacodontia–systematic revision and evolutionary implications | |
| MA52810A (fr) | Procédés d'utilisation de cd24 pour la prévention et le traitement de la maladie du greffon contre l'hôte et de la mucosite | |
| FR3049104B1 (fr) | Procede de diagnostic de maladies inflammatoires chroniques de l'intestin | |
| MA55595A (fr) | Composés pour le traitement du cancer induit par un oncovirus et leurs procédés d'utilisation | |
| FR3087772B1 (fr) | Nouveaux composes et leurs utilisations pour l'imagerie par la luminescence cherenkov proche infrarouge et/ou pour le traitement des tissus profonds par phototherapie dynamique cherenkov | |
| FR2917172B1 (fr) | Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation |